Proscia, a leading provider of digital and computational pathology solutions, has strengthened its position in the $12 billion preclinical research and development (R&D) market with enhancements to its flagship Concentriq for Research platform.
Concentriq for Research is trusted by 14 of the top 20 pharmaceutical companies as a singular software platform for pathology workflows and data. Preclinical R&D, which demonstrates if a drug is safe to advance to human clinical trials, centres around workflows with higher volumes of pathology data than any other phase of drug discovery and development. Life sciences organisations are now rapidly adopting digital pathology to drive efficiency and quality gains in their routine operations, streamlining collaboration and improving the reproducibility of results.
“Digital pathology is enabling preclinical pathology and R&D teams to do their jobs better,” said Aleksandra Zuraw, Veterinary Pathologist, Digital Pathologist, and Publisher of Digital Pathology Place. “By shifting from microscope to whole slide image, scientists can work more productively and deliver more consistent results.”
Proscia is extending the scalable, intuitive Concentriq for Research to increasingly drive preclinical R&D with new features and services including:
- Robust capabilities for GLP compliance
- A new ‘Studie’s module that streamlines toxicopathology workflows
- Expanded Automated Quality Control (QC) for preclinical image data.
“Expanding our solutions for preclinical R&D was an obvious step for us that came in response to growing customer demand,” said Nathan Buchbinder, Proscia’s Chief Product Officer. “These life sciences organisations are making important drug safety decisions that play a key role in getting new therapies to patients. We are now helping them to increasingly realise the efficiency and quality gains that Concentriq for Research delivers as the place where work happens and data lives.”
